Introduction
The annual costs for smoking related diseases are rising and have more than . It is generally considered that smoking cessation interventions are a cost effective way to save and prolong life 4, [7] [8] [9] [10] [11] [12] , research into the cost-effectiveness of provision across different settings is needed to explore the value of expanding provision outside of the dedicated NHS SSS.
The aim of this study is to compare the cost-effectiveness of smoking cessation services across dental, GMP, pharmacy and NHS SSS from the perspective of the NHS.
Material and Methods
The study used retrospective data collected from smoking cessation services across Bradford Metropolitan Borough in the North of England. Bradford is a multi-culturally diverse population whose economic landscape was severely compromised during the recession in the late 20 th Century; there remains areas of poor health status and this is evident when comparing morbidity and mortality in this location to England as a whole 13 .
The smoking cessation services across the region consist of NHS SSS and cessation services delivered within dental, GMP and pharmacy settings by dedicated and trained smoking cessation advisors, within each setting the services could be delivered by either GMPs, nurses, healthcare assistants, pharmacists and pharmacy advisors, dental nurses or receptionists. Each commissioned service receives smoking cessation training in compliance with standards laid out in the National
Framework to enable them to deliver advice and support to their clients 5 . The data recorded by the advisor outlined each contact with client together with pharmacotherapy prescribed; this was used to calculate the total cost of the advisors time for each client. The contact time for each appointment was based on contractual agreements with the commissioner. From the perspective of the NHS, costs, including pharmacotherapy, were obtained from national sources and a price year of 2011 used, no discounting was necessary given the duration was less than 12 months 15 . Details are given in Tables 1 and 2 .
Missing pharmacotherapy data was identified for clients attending the GMP service.
The reason for these missing data was due to the GMP system not requiring the types of pharmacotherapy to be recorded (this was optional). The GMP system only required a response of whether the client had received pharmacotherapy; yes or no.
The missing data was found in 23% (N=319) of client record entries, a mean pharmacotherapy cost was therefore calculated using the number of appointments attended by GMP clients and an average cost of pharmacotherapy (from GMP clients only), this mean cost for pharmacotherapy was applied to GMP clients with missing data.
In addition, the GMP dataset quit status did not differentiate between CO verified or self-report. A 'quit' status was applied to all clients who had quit and this accounted for 242 (17.5%) of the client database for GMPs (due to how the database was set up), therefore GMP services were excluded from scenario 1 and used within scenario 2 data where the data analysed assumed they were (1) CO verified; and (2) self-report combined ('quit') to enable a comparison across the settings using this generic 'quit' measure.
Sensitivity analyses were carried out to account for uncertainty in cost estimates by changing the cost pharmacotherapy by 20%. The value of 20% is essentially arbitrary given there was no historical data to draw on. However, it was considered likely to represent any uncertainty that might exist.
All data were analysed using SPSS 19. Ethical approval was obtained for this study from The National Research Ethics Service in the UK (REC reference:
05/Q1202/104).
Results
Smoking cessation service data identified 2,534 records of persons who attended smoking cessation services between July 2011 -December 2011 in Bradford, UK. Of our sample, 1,182 (47%) were male, age ranged from 16-87 (mean 41.18 years).
The client group were also categorised according to their 'deprivation status' which was generated from their postcode information using the Index of Multiple Deprivation (IMD). The minimum IMD score was 2.87 ('least deprived') and a maximum score of 81.07 ('most deprived') with a mean score of 38.03, these scores were clustered into quintiles ('least deprived' N=501, 'less deprived' N=505, 'average' N=510, 'more deprived' N=507 and 'most deprived' N=511). Clients from the most deprived IMD quintile (13%) attended dental settings the least, followed by pharmacy (12%), NHS SSS (15%) and the greatest proportion of clients from the most deprived quintile attended GMP services (26%). Clients categorised as 'least deprived' were more likely to attend dental and pharmacy services. The data showed that 55% of the sample attended GMP services (N=41 venues, N=95 advisors), 31% attended NHS SSS (N=46 venues, N=9 advisors), 11% attended pharmacy services (N=14 service venues, N=22 advisors) and 3% attended general dental practices (N=3 venues, N=3 advisors). The analysis undertaken made the assumption that all clients received a one-to-one service.
Cost to the provider
The costs of the advisor time for provision of smoking cessation advice across all settings are shown in Table 3 . The highest mean cost for advisor time was within NHS SSS (£51.93), the lowest in pharmacy (£28.90). However, the range of costs were wide, indicative of the wide range of number of sessions attended. As might be expected there was a statistically significant correlation observed between the mean number of sessions and cost (ANOVA, p=0.01). For all the providers with the exception of NHS SSS, there is also a contractual payment for provision of the service. This is shown in Table 4 . The payment exceeded the cost of the advisors time for dental providers and GMP providers.
Costs to the NHS
The cost to the NHS (Table 4) Incremental Cost-Effectiveness Ratio by setting
We used the cost to the NHS to calculate the ICERs using two scenarios; firstly only verified quits; and secondly verified and non-verified quits. The calculations compared each of the providers with the NHS SSS.
For verified quits (scenario 1), pharmacy services showed a lower mean cost per client and a higher proportion of CO verified quits than the other services. No figures were available for CO verified quits for GMP services and so they were excluded from this analysis.
For both verified and self-reported quits, whilst dental services show a slightly higher proportion of quits than NHS SSS, the mean cost per client was higher. The GMP services were dominated -by the NHS SSS, in as much as they are both less effective (a smaller proportion of quits and more expensive). This finding also holds true when we compared GMP services and pharmacy services.
Sensitivity analysis
There were 319 clients within the GMP setting with missing pharmacotherapy data (these data were not entered into client records but clients were noted as receiving pharmacotherapy). A sensitivity analysis was undertaken and the pharmacotherapy increased and decreased by 20%, this did not alter the results -the ICER remains dominated. Similarly a second sensitivity analysis in which all the pharmacotherapy costs were inflated and deflated by 20% did not alter interpretation of the results.
Discussion
There is an increasing requirement for cost-effectiveness analyses to support the development of services to ensure public monies are used appropriately 15 . The utility of smoking cessation services has been established through cost-effectiveness analyses where smokers who accessed NHS SSS in conjunction with pharmacotherapy were up to four times more likely to quit smoking (when compared to those who quit without professional support) 16, 17 .
Smoking cessation
interventions have also been assessed to be a cost effective way to save and prolong life 4, [7] [8] [9] [10] [11] [12] . However, research in understanding which service setting provide the most effective support to smokers to quit is in its infancy. Previous comparative cost-effectiveness analyses have used data from only two service settings (pharmacy: one-to-one interventions and NHS SSS: group interventions) 18, 19 . The findings from both comparative studies 19 showed that pharmacy services were less expensive and provided a cost effective intervention when compared to usual care . These studies are not directly comparable to the present research principally because they were conducted at different times and they compared group versus one-to-one interventions. However, they do demonstrate that cost effective smoking cessation interventions can be delivered by professionals in other healthcare settings rather than NHS SSS only.
The present comparative cost analysis identified costs to the provider and to the NHS for four service settings: dental, GMP, pharmacy and NHS SSS, this is the first time such an analysis has been undertaken.
For any publicly funded smoking cessation service inherent in its remit should be the reduction of health inequalities. Offering smoking cessation on a universal basis is unlikely to achieve this as suggested by the 'inverse care law'
20
.
Within the traditional delivery model in England 'demand' dictates delivery and placement of services rather than 'need', therefore those with the greatest health inequalities will access services in lower proportions to those who need it the least. Despite dental and pharmacy smoking cessation services which were sited in areas of high need and social deprivation, our analysis indicated that clients categorised as 'least deprived' were more likely to attend these providers for smoking cessation support.
Although all smoking cessation services were open to all, it is likely that only those accessing dental services for treatment would be aware of the smoking cessation service, this however is unlikely to apply to pharmacy services as they require no registration. The strength of this research lies in the pragmatic utilisation of an existing dataset that contains a wealth of information; this research demonstrates that further analysis of existing data could support service development. It should be acknowledged however, a possible drawback of using retrospective data. These include using a dataset for purposes other than why they were originally and the ability to reduce sample selection bias through randomisation is not available. Any There may be selection bias in operation as GMP services universally offer smoking cessation services whereas pharmacy and dental services were commissioned based on smoking prevalence, service capacity and location. This might have over inflated the quit rates in dental and pharmacy setting as they were placed in areas of deprivation and high need but conversely research shows that those who are more deprived also seek preventative services less frequently 20, 26 . It should also be noted that service choice of the clients was in operation, therefore a client could choose to access a service dependent on their needs. There is no available research which documents the patient journey and therefore it is not possible to isolate where clients had previously received smoking cessation advice. This research has assumed that services are mutually exclusive and therefore results are comparative, however it is essential to balance this view with possibility that multiple services may have supported one client to quit and therefore allocating a treatment outcome to one service alone may underplay the role that other services have had on that client's outcome.
As outlined earlier, each commissioned service received smoking cessation training in compliance with standards laid out in the National Framework to enable them to deliver advice and support to their clients issues when compared to a pharmacy assistant or dental nurse? These are questions for future research but should acknowledge when interpreting the research within this present analysis. We should also acknowledge a possible cluster effect based on the effectiveness of advisors which could increase the standard errors.
Whilst the use of retrospective data and the relatively small number of clients using smoking cessation services provided within dental and pharmacy setting does not allow us to address these questions, they should be considered in future research.
Within this research, from the perspective of the NHS, pharmacy services were considered cost-effective, dental services had high quit rates and high costs and GMP services lower quits and lower higher costs when compared to usual care (NHS SSS). For the service provider, payment from the NHS for providing the smoking cessation service exceeded the costs of the advisors time, with the exception of the pharmacy services; which is interesting given the payment system is the same in both. However, the results should be approached with caution given the relatively small sample sizes (and for the reasons already outlined). It is of note that dental services had higher pharmacotherapy costs and this is due to the use more than one pharmacotherapy product being used in combination, for example, gum and patches. Stead et al (2008) 27 found combining nicotine patches with another form of NRT was more effective than a single type of NRT and this in part could explain the higher quit rates seen in dental settings. When considering the role of remuneration, more research is required to assess if payment by results produces greater numbers of quitters than block contracts on a wider scale. Consideration to the impact on effectiveness based on contractual arrangements such as PbR and block contract should be considered in future research.
A trade-off between costs and effects may be a useful consideration when commissioning services, however other benefits should be considered such as facilitating access to a service, for example for hard to reach groups, then higher costs may be acceptable. This research has identified variations in service costs and effectiveness of services through the analysis a pragmatic dataset. Given the exploratory nature of this research, further research should explore the impact of service/location selection on uptake and cessation rates. 
